Neoplastic Processes: Clinical Trials

4,826 trials for Neoplastic Processes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2122 completed, 712 recruiting, 651 terminated, 626 unknown. 1809 Phase 2, 1521 Phase 1, 631 Not applicable, 427 Phase 3, 72 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21809Completed 789, Terminated 315, Recruiting 219, Unknown 181, Active not recruiting 135, Withdrawn 99, Not yet recruiting 60, Suspended 8, Enrolling by invitation 3
Phase 11521Completed 701, Terminated 275, Recruiting 242, Active not recruiting 111, Unknown 100, Withdrawn 48, Not yet recruiting 32, Suspended 10, Enrolling by invitation 2
Not applicable631Completed 248, Unknown 134, Recruiting 112, Terminated 48, Active not recruiting 35, Not yet recruiting 34, Withdrawn 19, Enrolling by invitation 1
Phase 3427Completed 198, Unknown 57, Recruiting 53, Terminated 51, Active not recruiting 43, Not yet recruiting 15, Withdrawn 7, Suspended 2, Enrolling by invitation 1
Phase 472Completed 36, Terminated 11, Unknown 11, Recruiting 8, Not yet recruiting 3, Withdrawn 3
Early Phase 146Completed 13, Terminated 11, Recruiting 9, Active not recruiting 4, Not yet recruiting 4, Withdrawn 3, Unknown 2

Follow Neoplastic Processes: new trials by email Literature Review of Neoplastic Processes trials Research Report on Neoplastic Processes

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer
Phase 1 / Phase 2Not yet recruitingCHU de Quebec-Universite Laval5002028-03-012025-03-30
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
SRS/fSRT+T-Dxd - Breast Cancer (Advanced/Metastatic)
Phase 2Not yet recruitingAzienda Ospedaliero-Universitaria Careggi602027-05-152026-10-29
Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options
Liver transplantation - Colorectal Neoplasms, Liver Neoplasms
Not applicableNot yet recruitingCharite University, Berlin, Germany2602027-04-012026-09-10
High Dose Radiotherapy for Palliation (Hi-D)
Palliative Radiotherapy - Metastases, Palliative Radiotherapy
Not applicableNot yet recruitingBritish Columbia Cancer Agency212027-03-012026-08-12
Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center
Discussion, Electronic Health Record Review, Questionnaire Administration - Metastatic Malignant Solid Neoplasm
Not yet recruitingM.D. Anderson Cancer Center2002027-01-302026-09-11
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer
Phase 1Not yet recruitingBaptist Health South Florida202027-01-012026-10-01
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase
Phase 2Not yet recruitingJohn Mascarenhas202027-01-012026-10-14
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Pancreatic Cancer, Advanced or Metastatic
Not yet recruitingUniversity of Maryland, Baltimore4502027-01-012026-11-06
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)
Phase 2Not yet recruitingGirish Dhall, MD252027-01-012026-10-28
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG
digital single-channel ECG recording - Atrial Fibrillation, Atrioventricular Block, Second and Third Degree
Not yet recruitingI.M. Sechenov First Moscow State Medical University3002026-12-312026-02-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1Not yet recruitingInSilico Medicine Hong Kong Limited1592026-12-302026-07-23
Adoption of Audio Recording in the Outpatient Supportive Care Center
Communication Intervention, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingM.D. Anderson Cancer Center2002026-12-302026-07-16
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma
Phase 2Not yet recruitingUniversity of Nebraska502026-12-122026-11-06
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
BON-106 - Solid Tumor, Advanced Solid Tumor
Phase 1Not yet recruitingBeOne Medicines962026-12-012026-10-26
Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma
LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Phase 2Not yet recruitingVA Office of Research and Development302026-12-012026-10-06
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
Epigenetic Assay - Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV)
Not yet recruitingUniversity of Maryland, Baltimore4502026-12-012026-09-10
Plant-Based Nutrition for Breast or Endometrial Cancer
Control, Whole Food, Plant-Based Diet with Behavioral Education and Support - Breast Cancer Metastatic, Endometrial Cancer Stage IV
Not applicableNot yet recruitingUniversity of Rochester602026-12-012026-04-08

Showing 20 of 4826. Sign in to see all of them.

Narrower conditions

Neoplasm Metastasis (3601)  ·  Neoplasms (729)  ·  Breast Neoplasms (711)  ·  Colorectal Neoplasms (497)  ·  Carcinoma, Non-Small-Cell Lung (408)  ·  Recurrence (368)  ·  Blast Crisis (356)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (332)  ·  Leukemia, Myeloid, Acute (322)  ·  Prostatic Neoplasms (307)  ·  Melanoma (303)  ·  Lung Neoplasms (294)  ·  Neoplasm, Residual (293)  ·  Pancreatic Neoplasms (266)  ·  Leukemia, Myeloid, Accelerated Phase (245)

Broader conditions

Pathological Conditions, Signs and Symptoms (4824)  ·  Pathologic Processes (4812)  ·  Neoplasms (4097)  ·  Neoplasms by Site (3105)  ·  Neoplasms by Histologic Type (1705)  ·  Digestive System Diseases (1134)  ·  Digestive System Neoplasms (1102)  ·  Skin and Connective Tissue Diseases (1015)  ·  Skin Diseases (1009)  ·  Neoplasms, Glandular and Epithelial (885)  ·  Urogenital Diseases (851)  ·  Gastrointestinal Diseases (826)  ·  Urogenital Neoplasms (806)  ·  Gastrointestinal Neoplasms (763)

Interventions

pembrolizumab (174)  ·  Cyclophosphamide (163)  ·  Gemcitabine (162)  ·  Paclitaxel (141)  ·  Capecitabine (136)  ·  Fluorouracil (126)  ·  Carboplatin (122)  ·  Bevacizumab (119)  ·  Oxaliplatin (119)  ·  Cisplatin (110)  ·  Docetaxel (109)  ·  Leucovorin (108)  ·  Nivolumab (104)  ·  Radiotherapy (100)  ·  Irinotecan (98)

Sponsors

M.D. Anderson Cancer Center (176)  ·  National Cancer Institute (NCI) (175)  ·  Memorial Sloan Kettering Cancer Center (74)  ·  Eli Lilly and Company (73)  ·  Novartis Pharmaceuticals (55)  ·  AstraZeneca (53)  ·  Fred Hutchinson Cancer Center (50)  ·  Pfizer (42)  ·  Fudan University (41)  ·  H. Lee Moffitt Cancer Center and Research Institute (39)  ·  University Health Network, Toronto (36)  ·  Amgen (32)  ·  City of Hope Medical Center (30)  ·  Dana-Farber Cancer Institute (26)  ·  UNC Lineberger Comprehensive Cancer Center (26)

Countries

United States (2489)  ·  France (592)  ·  China (585)  ·  Spain (439)  ·  Italy (378)  ·  Canada (375)  ·  Germany (357)  ·  United Kingdom (335)  ·  South Korea (289)  ·  Belgium (271)  ·  Australia (270)  ·  Netherlands (251)  ·  Taiwan (194)  ·  Poland (175)  ·  Japan (161)

Top investigators

Steven A Rosenberg, M.D. (13)

Results publications

PMID 36897458, PMID 33270906, PMID 37146227, PMID 37597578, PMID 28445469, PMID 32499241, PMID 34213592, PMID 38598571, PMID 38979716, PMID 41671463, PMID 12094370, PMID 14645423, PMID 15855973, PMID 17686822, PMID 18316791, PMID 18494054, PMID 19141862, PMID 20718753, PMID 21420083, PMID 21715313, PMID 21826194, PMID 22067397, PMID 22248721, PMID 22442346, PMID 22895629, PMID 23433878, PMID 23522151, PMID 23599758, PMID 24578254, PMID 24722180, PMID 24844673, PMID 24892406, PMID 24919854, PMID 25077927, PMID 25100135, PMID 25303679, PMID 25439688, PMID 25651787, PMID 25789053, PMID 26049686, PMID 26308596, PMID 26311728, PMID 26341722, PMID 26768165, PMID 27209293, PMID 27621408, PMID 28898379, PMID 29093181, PMID 29358182, PMID 30274985

NIH funding

2023 (59), 2019 (33), 2025 (30), 2017 (26), 2016 (25), P30CA016672 (24), P30CA033572 (22), 2014 (20), 2015 (20), P30CA043703 (20), 2018 (18), 2008 (17), P30CA015704 (14), UM1CA186709 (14), P30CA072720 (11)